Our findings suggest that tirzepatide, through its dual GIP/GLP-1 action, may be superior as a non-IOPlowering adjunct or even as a primary preventive agent in glaucoma management among patients with diabetes, the researchers wrote in their paper
Biermann has heard from many GLP-1 users who want to stop the medication and is studying whether gradually spacing out doses such as moving from weekly injections to every other week can help maintain weight loss and other health benefits
Evidence Summary: What the Data Suggest Several phase 2 and observational studies highlight the hepatic benefits of GLP1based treatment: Reduced liver fat: Repeated findings in imaging-based studies support this effect Lower liver enzymes: Consistent reductions in ALT/AST levels Fibrosis improvement: Promising trends in noninvasive markers, though further trials are needed While the strongest evidence comes from patients with obesity or type 2 diabetes, benefits in leaner, metabolically abnormal patients are increasingly documented, suggesting broader utility
We introduce recent studies that demonstrate the remarkable performance of GLP-1RAs in slowing the progression of neurodegenerative diseases, reducing inflammation, and enhancing cardiovascular health
In rare cases, it can lead to serious adverse reactions like pancreatitis, kidney injury, gallstones, gallbladder inflammation, facial swelling, and allergic reactions
This is not something you can control, test for, or change
